TAF1A

Across TCGA pan-cancer cohorts, TAF1A Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated TAF1A data layer compared with 29 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher TAF1A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TAF1A expression acts as an unfavorable survival marker.

MESO, ESCA, and COAD are the cancer types where TAF1A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.098	0.579	.001	36	view →
ESCA	DFS	Median	All	0.023	0.533	<.001	18	view →
COAD	OS	Median	II,III,IV	0.500	0.860	<.001	14	view →
LUSC	OS	Median	II,III,IV	0.002	0.743	<.001	12	view →
UCEC	OS	Median	IV	0.225	0.772	<.001	12	view →
SKCM	OS	Median	All	0.360	0.783	.005	9	view →
SCLC	OS	Median	All	0.082	0.653	.002	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

TAF1A–MESO (OS)

Open the MESO breakdown →